Adverum Biotechnologies, Inc. - Common Stock (ADVM)

Competitors to Adverum Biotechnologies, Inc. - Common Stock (ADVM)

Amgen Inc. 

Amgen is a leading biotechnology company that also explores gene therapies, notably in the ophthalmic sector. While Adverum focuses specifically on gene therapies for retinal conditions, Amgen leverages its vast resources, experience, and pipeline of established therapies, which places it in a favorable position against Adverum. The scale at which Amgen operates, coupled with its strong marketing capabilities and robust infrastructure, gives it a significant advantage over Adverum's niche offerings.

Astellas Pharma Inc.

Astellas Pharma engages in diverse therapeutic areas, including ophthalmology, where it offers several products that compete with Adverum's potential gene therapies. Astellas employs a robust global presence along with significant R&D investments, enabling it to maintain a competitive advantage in terms of market access and innovation. Adverum, being a smaller, specialized biotechnology firm, faces obstacles in scaling its capabilities to rival Astellas' established market position.

Novartis AG 

Novartis is a global healthcare company with extensive resources that compete with Adverum in the ophthalmology market, especially with its established product Lucentis (ranibizumab) for retinal diseases. Novartis' financial strength, diverse therapeutic portfolio, and greater market reach allow it to perform competitively in areas where Adverum is working to establish presence. As a large pharmaceutical company, Novartis holds a strong competitive advantage in terms of development speed and market access compared to Adverum's early-stage pipeline.

Regeneron Pharmaceuticals, Inc. 

Regeneron Pharmaceuticals and Adverum Biotechnologies compete in the field of gene therapies and ophthalmology treatments. Regeneron has a well-established portfolio, including EYLEA (aflibercept), which treats retinal diseases and generates significant revenue for the company. Adverum is focused on developing gene therapies for diseases like wet age-related macular degeneration (AMD) but is at an earlier stage in its development pipeline. Regeneron's established commercial success and strong R&D capabilities provide it with a significant competitive advantage over Adverum.

Santen Pharmaceutical Co., Ltd.

Santen Pharmaceutical specializes in the research, development, and marketing of ophthalmic products, similar to Adverum's focus on therapies for eye diseases. Santen's extensive product lineup and established market presence provide them with a robust platform compared to Adverum, which is still advancing its development stage therapies. While both companies aim to address retinal diseases, Santen's commercial footprint and existing therapeutic options grant it a competitive edge in the ophthalmic market.